Novartis invests in early technical improvement capabilities for next-generation biotherapeutics

Multi-year funding of USD 300m will create built-in scientific atmosphere to ship on growing progress and variety of biotherapeutics portfolio   Enhanced capability and processes anticipated to result in sooner transition instances from pre-clinical to first-in-human research Dedication to early section biologics improvement in Switzerland, Slovenia & Austria Basel, Sept 12, 2022 — Novartis right this … Read more